NCT04977310 is a NA clinical trial of CardioMEMS in Heart Failure, sponsored by STAVROS G DRAKOS.

Who is sponsoring NCT04977310?

NCT04977310 is sponsored by STAVROS G DRAKOS.

What drugs are being tested in NCT04977310?

Interventions in NCT04977310: CardioMEMS.

What condition does NCT04977310 study?

NCT04977310 studies Heart Failure.

Is NCT04977310 still recruiting?

NCT04977310 is currently withdrawn. Last updated 16 December 2024.

Last reviewed 2024-12-16 · How we verify

NCT04977310

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TARGET-LOAD Pilot Study Comparing Hemodynamics-guided LVAD Unloading Vs. Standard of Care

Withdrawn NA Last updated 16 December 2024

What this trial tests

NA trial testing CardioMEMS in Heart Failure. Withdrawn.

Timeline

31 March 2025

Primary endpoint
1 September 2026

1 September 2026

Quick facts

Lead sponsor	STAVROS G DRAKOS
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	31 March 2025
Primary completion	1 September 2026
Estimated completion	1 September 2026
Sites	2 locations across United States

Drugs / interventions tested

CardioMEMS

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

STAVROS G DRAKOS

Who can join

Adults 18 to 60, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, randomized-controlled, non-blinded, multi-center, pilot trial to compare standard-of-care left ventricular assist device (LVAD) unloading plus heart failure (HF) medications reverse-remodeling management versus hemodynamics-guided LVAD unloading with use of the wireless monitoring system CardioMEMS plus HF medications reverse-remodeling management.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CardioMEMS

Trials testing the same drug.

NCT04570865 — Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS · Phase 4 · unknown

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other STAVROS G DRAKOS trials

Trials by the same sponsor.

NCT05185492 — Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock · recruiting
NCT03238690 — LVAD Conditioning for Cardiac Recovery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04977310 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by STAVROS G DRAKOS
Last refreshed: 16 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04977310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing